Literature DB >> 24314710

[Cypress pollen allergy].

D Charpin1, M Calleja, C Pichot, V Penel, B Hugues, P Poncet.   

Abstract

Cypress belongs to the Cupressaceae family, which includes 140 species with non-deciduous foliage. The most important genera in allergic diseases are Cupressus sempervirens or Green cypress, Cupressus arizonica or Blue cypress, Juniperus oxycedrus, Juniperus communis and Thuya. Because J. oxycedrus pollinates in October, C. sempervirens in January and February, C. arizonica in February and March, J. communis in April, the symptomatic period is long-lasting. Because of global warming, the pollination period is tending to last longer and Cupressaceae species are becoming established further the north. In Mediterranean countries, cypress is by far the most important pollinating species, accounting for half of the total pollination. The major allergens belong to group 1. The other allergens from cypress and Juniper share 75 to 97 % structural homology with group 1 major allergens. The prevalence of cypress allergy in the general population ranges from 5 % to 13 %, according to exposure to the pollen. Among outpatients consulting an allergist, between 9 and 35 %, according to different studies, are sensitized to cypress pollen. Repeated cross-sectional studies performed at different time intervals have demonstrated a threefold increase in the percentage of cypress allergy. Risk factors include a genetic predisposition and/or a strong exposure to pollen, but air pollutants could play a synergistic role. The study of the natural history of cypress allergy allows the identification of a subgroup of patients who have no personal or family history of atopy, whose disease began later in life, with low total IgE and often monosensitization to cypress pollen. In these patients, the disease is allergic than rather atopic. In the clinical picture, rhinitis is the most prevalent symptom but conjunctivitis the most disabling. A cross-reactivity between cypress and peach allergy has been demonstrated. The pharmacological treatment of cypress allergy is not different from that for other allergies. Hyposensitization has been used, at first by injection, but nowadays mostly through the sublingual route, but clinical trials have included few patients. Avoidance can be implemented at the individual level but also at the community levels using alternative plants, low-pollinating cypresses or by trimming hedges prior to pollination.
Copyright © 2013. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Allergie; Allergy; Cypress; Cyprès; Health; Pollen; Pollinoses; Pollinosis; Santé

Mesh:

Substances:

Year:  2013        PMID: 24314710     DOI: 10.1016/j.rmr.2013.09.014

Source DB:  PubMed          Journal:  Rev Mal Respir        ISSN: 0761-8425            Impact factor:   0.622


  3 in total

1.  Temporal modelling and forecasting of the airborne pollen of Cupressaceae on the southwestern Iberian Peninsula.

Authors:  Inmaculada Silva-Palacios; Santiago Fernández-Rodríguez; Pablo Durán-Barroso; Rafael Tormo-Molina; José María Maya-Manzano; Ángela Gonzalo-Garijo
Journal:  Int J Biometeorol       Date:  2015-06-21       Impact factor: 3.787

2.  Prevalence of allergic sensitization to conifer pollen in a high cypress exposure area.

Authors:  Javier Domínguez-Ortega; María Ángeles López-Matas; María Dolores Alonso; Angélica Feliú; Javier Ruiz-Hornillos; Emma González; Raquel Moya; Jerónimo Carnés
Journal:  Allergy Rhinol (Providence)       Date:  2016-01-01

3.  Estimation of the Allergenic Potential of Urban Trees and Urban Parks: Towards the Healthy Design of Urban Green Spaces of the Future.

Authors:  Paloma Cariñanos; Filipa Grilo; Pedro Pinho; Manuel Casares-Porcel; Cristina Branquinho; Nezha Acil; María Beatrice Andreucci; Andreia Anjos; Pietro Massimiliano Bianco; Silvia Brini; Pedro Calaza-Martínez; Enrico Calvo; Elisa Carrari; José Castro; Anna Chiesura; Otilia Correia; Artur Gonçalves; Paula Gonçalves; Teresa Mexia; Marzia Mirabile; Elena Paoletti; Margarida Santos-Reis; Paolo Semenzato; Ursa Vilhar
Journal:  Int J Environ Res Public Health       Date:  2019-04-15       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.